Want to see TFX full AI Analyst Report?
TFX Stock Chart & Stats
$131.58
-$2.38(-1.33%)
At close: 4:00 PM EST
$131.58
-$2.38(-1.33%)
Day’s Range― - ―
52-Week Range$100.18 - $139.67
Previous CloseN/A
Volume73.33K
Average Volume (3M)663.22K
Market Cap
$5.93B
Enterprise Value$7.91B
Total Cash (Recent Filing)$309.41M
Total Debt (Recent Filing)$2.69B
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume502,237
30 Day Avg. Volume663,219
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit5.28
Enterprise Value/Ebitda-89.39
Forecast
1Y Price Target
$146.00Price Target Upside10.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)6.7
Revenue Forecast (FY)$2.29B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow provides durable internal funding for operations, R&D and capital allocation. This cash cushion supports planned debt reduction and buybacks, reducing reliance on external financing and improving long-term financial flexibility even while GAAP earnings are stressed.
Material Divestiture Proceeds PlannedProceeds from announced divestitures materially reshape the balance sheet and funding capacity. The $1.8B is earmarked for share repurchases and ~$800M debt paydown, which will lower leverage, reduce interest burden and free capital to focus on core vascular, interventional and surgical franchises long-term.
Experienced CEO And Board RefreshA permanent CEO with deep industry and vascular experience strengthens execution capability for the company’s strategic pivot. Leadership with relevant commercial and product-launch expertise increases odds of smoother integration, faster commercialization and better operational discipline across the refocused portfolio.
Bears Say
Severe Profitability DeteriorationDeep negative margins and negative EBITDA signal fundamental earnings weakness that can persist beyond short-term cycles. Sustained losses erode retained capital, depress returns on equity and constrain reinvestment capacity, making margin recovery and credible long-term profitability the central execution risk.
Material Margin Compression And Remediation CostsLarge margin headwinds from tariffs, supplier remediation and higher distribution costs materially reduce sustainable operating profitability. These structural cost pressures, plus lower-margin acquisition mix and stranded costs, can depress adjusted margins and cash flow for multiple quarters absent successful restructuring.
Regulatory/timing Risk To Strategic ProceedsRegulatory reviews and potential delays to divestiture closings threaten the timing of ~$1.8B proceeds. A postponed or altered sale timeline would delay debt reduction and buybacks, keep leverage and interest costs elevated, and extend exposure to stranded costs and integration disruption.
Teleflex News
TFX FAQ
What was Teleflex’s price range in the past 12 months?
Teleflex lowest stock price was $100.18 and its highest was $139.67 in the past 12 months.
What is Teleflex’s market cap?
Teleflex’s market cap is $5.93B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Jul 30, 2026 which is in 25 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on May 07, 2026. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.176.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex pays a Quarterly dividend of $0.34 which represents an annual dividend yield of 1.11%. See more information on Teleflex dividends here
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.27.
How many shares outstanding does Teleflex have?
Teleflex has 44,270,210 shares outstanding.
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.39 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went up 6.857%.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in TFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$146.00 (10.96% Upside)
$146.00 (10.96% Upside)
Blogger Sentiment
Bullish
TFX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.46%
12-Months-Change
Fundamentals
Return on Equity
-28.27%
Trailing 12-Months
Asset Growth
-5.31%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TFX Company Deck
TFX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.View all TFX earnings summariesTFX Stock 12 Month Forecast
Average Price Target
$146.00
▲(10.96% Upside)
Technical Analysis
Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―
Ownership Overview
0.57% Insiders
35.14% Mutual Funds
<0.01% Other Institutional Investors
41.94% Public Companies and
Individual Investors